Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Change in Accured Expenses (2016 - 2024)

Historic Change in Accured Expenses for Sanara MedTech (SMTI) over the last 14 years, with Q1 2024 value amounting to -$783390.0.

  • Sanara MedTech's Change in Accured Expenses rose 5981.22% to -$783390.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $1.1 million, marking a year-over-year decrease of 2545.83%. This contributed to the annual value of -$81513.0 for FY2023, which is 10272.21% down from last year.
  • As of Q1 2024, Sanara MedTech's Change in Accured Expenses stood at -$783390.0, which was up 5981.22% from $1.6 million recorded in Q4 2023.
  • Sanara MedTech's Change in Accured Expenses' 5-year high stood at $1.6 million during Q4 2023, with a 5-year trough of -$1.9 million in Q1 2023.
  • In the last 5 years, Sanara MedTech's Change in Accured Expenses had a median value of $325788.0 in 2020 and averaged $231970.4.
  • In the last 5 years, Sanara MedTech's Change in Accured Expenses plummeted by 38023.87% in 2020 and then soared by 41996.86% in 2022.
  • Over the past 5 years, Sanara MedTech's Change in Accured Expenses (Quarter) stood at $524534.0 in 2020, then fell by 12.61% to $458405.0 in 2021, then soared by 222.35% to $1.5 million in 2022, then increased by 7.75% to $1.6 million in 2023, then crashed by 149.2% to -$783390.0 in 2024.
  • Its Change in Accured Expenses stands at -$783390.0 for Q1 2024, versus $1.6 million for Q4 2023 and $185400.0 for Q3 2023.